The estimated Net Worth of David A Ramsay is at least $14 millió dollars as of 24 May 2023. Mr. Ramsay owns over 100,000 units of La Jolla Pharmaceutical Co stock worth over $13,691,103 and over the last 17 years he sold LJPC stock worth over $199,900. In addition, he makes $154,647 as Independent Director at La Jolla Pharmaceutical Co.
David has made over 44 trades of the La Jolla Pharmaceutical Co stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of LJPC stock worth $259,000 on 24 May 2023.
The largest trade he's ever made was buying 689,655 units of La Jolla Pharmaceutical Co stock on 15 March 2021 worth over $1,000,000. On average, David trades about 43,341 units every 97 days since 2007. As of 24 May 2023 he still owns at least 2,201,142 units of La Jolla Pharmaceutical Co stock.
You can see the complete history of Mr. Ramsay stock trades at the bottom of the page.
David Ramsay CPA serves as Independent Director of the Company. Since 2011, he has served as a director of Savara, Inc. In 2018, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. From 2003 to 2015, he held various positions at Halozyme Therapeutics, Inc., most recently serving as Chief Financial Officer. From 2000 to 2003, Mr. Ramsay served as Vice President, Chief Financial Officer of Lathian Systems, Inc. From 1998 to 2000, he served as Vice President, Treasurer and Director, Corporate Finance at Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.). Mr. Ramsay began his career at Deloitte & Touche LLP. Mr. Ramsay received a B.S. in business administration from the University of California, Berkeley, an MBA in finance and strategic management from the Wharton School of the University of Pennsylvania and is a Certified Public Accountant (inactive) in the state of California. The Board has concluded that Mr. Ramsay should serve as a director based on his experience serving as a director of biotechnology companies and his expertise in financial management.
As the Independent Director of La Jolla Pharmaceutical Co, the total compensation of David Ramsay at La Jolla Pharmaceutical Co is $154,647. There are 3 executives at La Jolla Pharmaceutical Co getting paid more, with Larry G. Edwards having the highest compensation of $749,170.
David Ramsay is 55, he's been the Independent Director of La Jolla Pharmaceutical Co since 2019. There are 6 older and 4 younger executives at La Jolla Pharmaceutical Co. The oldest executive at La Jolla Pharmaceutical Co. is Robert Rosen, 64, who is the Independent Director.
David's mailing address filed with the SEC is ONE SUMMIT SQUARE,, 1717 LANGHORNE NEWTOWN ROAD, SUITE 300, LANGHORNE, PA, 19047.
Over the last 21 years, insiders at La Jolla Pharmaceutical Co have traded over $13,460,170 worth of La Jolla Pharmaceutical Co stock and bought 11,640,515 units worth $137,250,039 . The most active insiders traders include Advisors Llcperceptive Life..., James N Topper és Woodlands Health Ventures F.... On average, La Jolla Pharmaceutical Co executives and independent directors trade stock every 63 days with the average trade being worth of $1,249,971. The most recent stock trade was executed by Craig A Johnson on 8 July 2022, trading 12,000 units of LJPC stock currently worth $47,160.
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
La Jolla Pharmaceutical Co executives and other stock owners filed with the SEC include: